title: Acetazolamide therapy for metabolic alkalosis in critically ill pediatric patients.
abstract: OBJECTIVE
  Despite a paucity of supporting literature, acetazolamide is commonly used in critically ill children with metabolic alkalosis (elevated plasma bicarbonate [pHco-3] and pH). The objective of this study was to assess the change in 18 hours after initiation of acetazolamide therapy.
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  PICU of an urban, tertiary-care children's hospital.
  
  
  METHODS
  Mechanically ventilated children (≤ 17 yr) with metabolic alkalosis (pHco-3 ≥ 35 mmol/L).
  
  
  METHODS
  None.
  
  
  RESULTS
  Of 153 consecutively screened patients, 61 patients (29 female patients) were enrolled: 18 cardiac patients (after congenital heart disease repair) and 43 noncardiac patients. The cardiac patients were younger than the noncardiac patients (median [interquartile range] age, 0.6 mo [0.3-2.5 mo] vs 7.4 mo [2.8-39.9 mo]; p < 0.00001) and had higher preacetazolamide baseline diuretic scores and urine output. The pHco-3 levels 18 hours after initiation of acetazolamide were reduced in the cohort as a whole (40.2 ± 4.8 to 36.2 ± 5.6 mmol/L; p < 0.001) and in the noncardiac patients, but they were unchanged in the cardiac patients. The PCO2 remained unchanged after acetazolamide in both subgroups. Because young age and presence of cardiac disease were potential confounders, the 20 noncardiac patients who are 6 months old or younger were compared with the cardiac subgroup and demonstrated reduced pHco-3 after acetazolamide and lower preacetazolamide baseline diuretic score and urine output.
  
  
  CONCLUSIONS
  Acetazolamide reduces pHco-3 concentration in critically ill, mechanically ventilated children overall, but it did not do so in cardiac patients in our cohort, even in comparison with noncardiac patients of a similar age. These findings do not support the current use of acetazolamide for metabolic alkalosis in critically ill children with congenital heart disease. Further study is required to determine why these cardiac patients respond differently to acetazolamide than noncardiac patients and whether this response impacts important clinical outcomes, for example, weaning mechanical ventilation.
authors: 1Section of Pediatric Critical Care Medicine, Drexel University College of Medicine/St. Christopher's Hospital for Children, Philadelphia, PA. 2Department of Pathology and Laboratory Medicine, Drexel University College of Medicine/St. Christopher's Hospital for Children, Philadelphia, PA. 3Sleep Disorders Center, Drexel University College of Medicine/St. Christopher's Hospital for Children, Philadelphia, PA. 4Division of Pediatric Critical Care Medicine, New York University Langone Medical Center, New York, NY. 5Department of Pediatrics, New York University School of Medicine, New York, NY.
authors: Amir
authors: A
authors: Bar
authors: Jeff
authors: J
authors: Cies
authors: Kathleen
authors: K
authors: Stapleton
authors: Danna
authors: D
authors: Tauber
authors: Arun
authors: A
authors: Chopra
authors: Paul M
authors: PM
authors: Shore
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use*; D000471:Alkalosis / Q000188:drug therapy*; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D002675:Child, Preschool; D016638:Critical Illness; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D012121:Respiration, Artificial; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide